ConductScience.org, home

Trial · NCT03840902

Adverse events732

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherAnaemiaBlood and lymphatic system disorderscCRT Plus M7824 Followed by M7824387449
otherAnaemiaBlood and lymphatic system disorderscCRT Plus Placebo Followed by Durvalumab327753
otherFebrile neutropeniaBlood and lymphatic system disorderscCRT Plus M7824 Followed by M78241741
otherFebrile neutropeniaBlood and lymphatic system disorderscCRT Plus Placebo Followed by Durvalumab0770
otherIron deficiency anaemiaBlood and lymphatic system disorderscCRT Plus M7824 Followed by M78241741
otherIron deficiency anaemiaBlood and lymphatic system disorderscCRT Plus Placebo Followed by Durvalumab0770
otherLeukopeniaBlood and lymphatic system disorderscCRT Plus M7824 Followed by M782497413
otherLeukopeniaBlood and lymphatic system disorderscCRT Plus Placebo Followed by Durvalumab107712
otherLymphopeniaBlood and lymphatic system disorderscCRT Plus M7824 Followed by M78244744
otherLymphopeniaBlood and lymphatic system disorderscCRT Plus Placebo Followed by Durvalumab3773
otherNeutropeniaBlood and lymphatic system disorderscCRT Plus M7824 Followed by M7824207427
otherNeutropeniaBlood and lymphatic system disorderscCRT Plus Placebo Followed by Durvalumab157718
otherPancytopeniaBlood and lymphatic system disorderscCRT Plus M7824 Followed by M78241741
otherPancytopeniaBlood and lymphatic system disorderscCRT Plus Placebo Followed by Durvalumab1772
otherThrombocytopeniaBlood and lymphatic system disorderscCRT Plus M7824 Followed by M7824117416
otherThrombocytopeniaBlood and lymphatic system disorderscCRT Plus Placebo Followed by Durvalumab7778
otherAngina pectorisCardiac disorderscCRT Plus M7824 Followed by M78242743
otherAngina pectorisCardiac disorderscCRT Plus Placebo Followed by Durvalumab0770
otherAtrial fibrillationCardiac disorderscCRT Plus M7824 Followed by M78242742
otherAtrial fibrillationCardiac disorderscCRT Plus Placebo Followed by Durvalumab1771

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03840902/events